SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Sarah L. Greig, Emma D. Deeks, Abacavir/Dolutegravir/Lamivudine Single-Tablet Regimen: A Review of Its Use in HIV-1 Infection, Drugs, 2015, 75, 5, 503

    CrossRef

  2. 2
    Susana W Keeshin, Judith Feinberg, Evaluation of dolutegravir safety for the treatment of HIV-1, Expert Opinion on Drug Safety, 2015, 14, 1, 141

    CrossRef

  3. 3
    Jean-Michel Molina, Bonaventura Clotet, Jan van Lunzen, Adriano Lazzarin, Matthias Cavassini, Keith Henry, Valeriv Kulagin, Naomi Givens, Carlos Fernando de Oliveira, Clare Brennan, Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study, The Lancet HIV, 2015, 2, 4, e127

    CrossRef

  4. 4
    Marcel Lee, Florian Eyer, Norbert Felgenhauer, Hartwig HF Klinker, Christoph D Spinner, Overdose of dolutegravir in combination with tenofovir disaproxil fumarate/emtricitabine in suicide attempt in a 21-year old patient, AIDS Research and Therapy, 2015, 12, 1

    CrossRef

  5. 5
    Jianxing Zhao, Simultaneous determination of plasma creatinine, uric acid, kynurenine and tryptophan by high-performance liquid chromatography: method validation and in application to the assessment of renal function, Biomedical Chromatography, 2015, 29, 3
  6. 6
    Stephen G Holt, David M Gracey, Miriam T Levy, David W Mudge, Ashley B Irish, Rowan G Walker, Richard Baer, Jacob Sevastos, Riaz Abbas, Mark A Boyd, A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection, AIDS Research and Therapy, 2014, 11, 1, 35

    CrossRef

  7. 7
    David A. Wohl, Calvin Cohen, Joel E. Gallant, Anthony Mills, Paul E. Sax, Edwin DeJesus, Andrew Zolopa, Hui C. Liu, Andrew Plummer, Kirsten L. White, Andrew K. Cheng, Martin S. Rhee, Javier Szwarcberg, A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2014, 65, 3, e118

    CrossRef

  8. 8
    Jean C. Yombi, Anton Pozniak, Marta Boffito, Rachael Jones, Saye Khoo, Jeremy Levy, Frank A. Post, Antiretrovirals and the kidney in current clinical practice, AIDS, 2014, 28, 5, 621

    CrossRef

  9. 9
    Eve-Irene Lepist, Xuexiang Zhang, Jia Hao, Jane Huang, Alan Kosaka, Gabriel Birkus, Bernard P Murray, Roy Bannister, Tomas Cihlar, Yong Huang, Adrian S Ray, Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat, Kidney International, 2014, 86, 2, 350

    CrossRef

  10. 10
    Vikram Arya, Jeffry Florian, Kendall A. Marcus, Kellie S. Reynolds, Linda L. Lewis, Adam I. Sherwat, Does an Increase in Serum Creatinine always Reflect Renal Injury? The Case of Stribild®, The Journal of Clinical Pharmacology, 2014, 54, 3
  11. 11
    Dennis Cada, Terri Levien, Danial Baker, Dolutegravir, Hospital Pharmacy, 2014, 49, 2, 184

    CrossRef

  12. 12
    Jose Vicente Fernandez-Montero, Pablo Barreiro, Pablo Labarga, Carmen De Mendoza, Vicente Soriano, Dolutegravir, abacavir and lamivudine as HIV therapy, Expert Opinion on Pharmacotherapy, 2014, 15, 7, 1051

    CrossRef

  13. 13
    Dorothy E. Dow, John A. Bartlett, Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV, Infectious Diseases and Therapy, 2014, 3, 2, 83

    CrossRef

  14. 14
    Bhavik M. Shah, Jason J. Schafer, Joseph A. DeSimone, Dolutegravir: A New Integrase Strand Transfer Inhibitor for the Treatment of HIV, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014, 34, 5
  15. 15
    D. A. Osterholzer, M. Goldman, Dolutegravir: A Next-Generation Integrase Inhibitor for Treatment of HIV Infection, Clinical Infectious Diseases, 2014, 59, 2, 265

    CrossRef

  16. 16
    Paul L. McCormack, Dolutegravir: A Review of Its Use in the Management of HIV-1 Infection in Adolescents and Adults, Drugs, 2014, 74, 11, 1241

    CrossRef

  17. 17
    L. Curtis, G. Nichols, C. Stainsby, J. Lim, A. Aylott, B. Wynne, A. Clark, M Bloch, G. Maechler, L.. Martin-Carpenter, F. Raffi, S. Min, Dolutegravir: Clinical and Laboratory Safety in Integrase Inhibitor–Naive Patients, HIV Clinical Trials, 2014, 15, 5, 199

    CrossRef

  18. 18
    José Vicente Fernández-Montero, Eugenia Vispo, Vicente Soriano, Emerging antiretroviral drugs, Expert Opinion on Pharmacotherapy, 2014, 15, 2, 211

    CrossRef

  19. 19
    Anton L Pozniak, Jose R Arribas, FLAMINGO: how much rosier can antiretroviral therapy get?, The Lancet, 2014, 383, 9936, 2191

    CrossRef

  20. 20
    Girish N. Nadkarni, Ioannis Konstantinidis, Christina M. Wyatt, HIV and the aging kidney, Current Opinion in HIV and AIDS, 2014, 9, 4, 340

    CrossRef

  21. 21
    Sean E. Collins, Philip M. Grant, Eugene T. Richardson, Andrew R. Zolopa, Integrating Integrase Inhibitors Into an Antiretroviral Regimen, Current Treatment Options in Infectious Diseases, 2014, 6, 2, 144

    CrossRef

  22. 22
    Bonaventura Clotet, Judith Feinberg, Jan van Lunzen, Marie-Aude Khuong-Josses, Andrea Antinori, Irina Dumitru, Vadim Pokrovskiy, Jan Fehr, Roberto Ortiz, Michael Saag, Julia Harris, Clare Brennan, Tamio Fujiwara, Sherene Min, Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study, The Lancet, 2014, 383, 9936, 2222

    CrossRef

  23. 23
    Paolo Maggi, Vincenzo Montinaro, Stefano Rusconi, Antonio Di Biagio, Rita Bellagamba, Paolo Bonfanti, Leonardo Calza, Paola Corsi, Francesco Montella, Cristina Mussini, The Problem of Renal Function Monitoring in Patients Treated With the Novel Antiretroviral Drugs, HIV Clinical Trials, 2014, 15, 3, 87

    CrossRef

  24. 24
    Darren M. Moss, Megan Neary, Andrew Owen, The role of drug transporters in the kidney: lessons from tenofovir, Frontiers in Pharmacology, 2014, 5,

    CrossRef

  25. 25
    I.D. Ramsay, J.M. Lestner, C.I.S. Barker, A worldwide yearly survey of new data in adverse drug reactions and interactions, 2014,

    CrossRef

  26. 26
    Mackenzie L. Cottrell, Tanja Hadzic, Angela D. M. Kashuba, Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir, Clinical Pharmacokinetics, 2013, 52, 11, 981

    CrossRef

  27. 27
    Ivy Song, Stephen Mark, Shuguang Chen, Paul Savina, Toshihiro Wajima, Amanda Peppercorn, Urmilla Bala, Pierre Geoffroy, Stephen Piscitelli, Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects, Drug and Alcohol Dependence, 2013, 133, 2, 781

    CrossRef

  28. 28
    Hans-Jürgen Stellbrink, Jacques Reynes, Adriano Lazzarin, Eugene Voronin, Federico Pulido, Franco Felizarta, Steve Almond, Marty St Clair, Nancy Flack, Sherene Min, Dolutegravir in antiretroviral-naive adults with HIV-1, AIDS, 2013, 27, 11, 1771

    CrossRef

  29. 29
    Sharon L. Walmsley, Antonio Antela, Nathan Clumeck, Dan Duiculescu, Andrea Eberhard, Felix Gutiérrez, Laurent Hocqueloux, Franco Maggiolo, Uriel Sandkovsky, Catherine Granier, Keith Pappa, Brian Wynne, Sherene Min, Garrett Nichols, Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection, New England Journal of Medicine, 2013, 369, 19, 1807

    CrossRef

  30. 30
    Pedro Cahn, Anton L Pozniak, Horacio Mingrone, Andrey Shuldyakov, Carlos Brites, Jaime F Andrade-Villanueva, Gary Richmond, Carlos Beltran Buendia, Jan Fourie, Moti Ramgopal, Debbie Hagins, Franco Felizarta, Jose Madruga, Tania Reuter, Tamara Newman, Catherine B Small, John Lombaard, Beatriz Grinsztejn, David Dorey, Mark Underwood, Sandy Griffith, Sherene Min, Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study, The Lancet, 2013, 382, 9893, 700

    CrossRef

  31. 31
    Samir K. Gupta, Deming Mi, Sharon M. Moe, Michael P. Dubé, Ziyue Liu, Effects of Switching From Efavirenz to Raltegravir on Endothelial Function, Bone Mineral Metabolism, Inflammation, and Renal Function, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2013, 64, 3, 279

    CrossRef

  32. 32
    François Raffi, Hans Jaeger, Eugenia Quiros-Roldan, Helmut Albrecht, Elena Belonosova, Jose M Gatell, Jean-Guy Baril, Pere Domingo, Clare Brennan, Steve Almond, Sherene Min, Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial, The Lancet Infectious Diseases, 2013, 13, 11, 927

    CrossRef

  33. 33
    Charles Flexner, Michael Saag, The antiretroviral drug pipeline, Current Opinion in HIV and AIDS, 2013, 8, 6, 572

    CrossRef